Europos Sąjunga - norvegų - EMA (European Medicines Agency)

mylan dura gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom.

Europos Sąjunga - norvegų - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiske midler - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Europos Sąjunga - norvegų - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Europos Sąjunga - norvegų - EMA (European Medicines Agency)

pharmathen s.a. - ibandronsyre - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - legemidler til behandling av bein sykdommer - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. behandling av tumor-indusert hyperkalsemi med eller uten metastaser. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Norvegija - norvegų - Statens legemiddelverk

csl behring gmbh (2) - c1-esteraseinhibitor, human - pulver og væske til injeksjonsvæske, oppløsning - 3000 iu

Norvegija - norvegų - Statens legemiddelverk

csl behring gmbh (2) - c1-esteraseinhibitor, human - pulver og væske til injeksjonsvæske, oppløsning - 2000 iu

Europos Sąjunga - norvegų - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - ambrisentan - hypertensjon, pulmonal - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.

Norvegija - norvegų - Statens legemiddelverk

mip pharma gmbh - cefepimdihydrokloridmonohydrat - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g

Norvegija - norvegų - Statens legemiddelverk

mip pharma gmbh - cefepimdihydrokloridmonohydrat - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g

Norvegija - norvegų - Statens legemiddelverk

mip pharma gmbh - cefuroksimnatrium - pulver til injeksjonsvæske, oppløsning - 750 mg